Gina Barzen

Gina Barzen

Auto-generated profile, based on publicly available information

Gina Barzen

Charité—Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, 10117 Berlin, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HPHelena Franziska Pernice
Helena Franziska Pernice
AKAdrian L. Knorz
Adrian L. Knorz
PWPaul J. Wetzel
Paul J. Wetzel
CHCarolin Herrmann
Carolin Herrmann
HMHarisa Muratovic
Harisa Muratovic
KHKatrin Hahn
Katrin Hahn
In contrast to inherited transthyretin amyloidosis (A-ATTRv), neuropathy is not a classic leading symptom of wild type transthyretin amyloidosis (A-ATTRwt). However, neurological symptoms are increasingly relevant in A-ATTRwt as well. To better understand the role of neurological symptoms in A-ATTRwt, A-ATTRwt patients were prospectively characterized at Amyloidosis Center Charité Berlin (ACCB) between 2018 and 2023 using detailed neurological examination, quality of life questionnaires, and analysis of age- and BMI-adapted serum neurofilament light chain (NFL) levels. 16 out of 73 (21.9%) patients presented with a severe neuropathy which we defined by a Neuropathy Impairment Score (NIS) of 20 or more. In this group, quality of life was reduced, peripheral neuropathy was more severe, and spinal stenosis and joint replacements were frequent. Age- and BMI matched serum NFL levels were markedly elevated in patients with a NIS ≥ 20. We therefore conclude that highly abnormal values in neuropathy scores such as the NIS occur in A-ATTRwt, and have an important impact on quality of life. Both peripheral neuropathy and spinal canal stenosis are likely contributors. Serum NFL may serve as a biomarker for neurological affection in patients with A-ATTRwt. It will be important to consider neurological aspects of A-ATTRwt for diagnosis, clinical follow-up, and future treatment development.

19 February 2026 in Digital Health
Verified
Journal Article
Open access
SMSusann May
Susann May
FMFelix Muehlensiepen
Felix Muehlensiepen
GBGina Barzen
Gina Barzen
FSFrances Seifert
Frances Seifert
MMManuela Marquardt
Manuela Marquardt
SSSebastian Spethmann
Sebastian Spethmann
Background: This manuscript presents the study protocol for a planned mixed-methods study on the transition to an opt-out approach for the electronic health record (elektronische Patientenakte, ePA) in Germany in 2025. This change represents a paradigm shift in the healthcare system and aims to promote broad adoption. While the ePA has the potential to improve cross-sectoral care and patient empowerment, structural and individual barriers may hinder successful implementation. Understanding these factors is crucial to developing strategies for effective integration and long-term utilization of the ePA. Objective: This study aims to systematically investigate the barriers and facilitators influencing the adoption and use of the ePA among various user groups, including both patients and healthcare providers, in Germany. It seeks to identify sociodemographic and contextual factors affecting acceptance and usage while also exploring the ePAs potential to optimize healthcare processes, patient satisfaction, and empowerment. Methods: This mixed-methods exploratory study employs the Consolidated Framework for Implementation Research to examine the structural, organizational, and individual determinants of ePA implementation. Data will be collected in four modules: (1) patient interviews and surveys with ePA users and nonusers, (2) analysis of aggregated usage data from all ePAs in Germany, (3) interviews and surveys with stakeholders in outpatient and emergency care, and (4) focus groups for validation and synthesis of findings. Quantitative analyses include descriptive statistics and regression models, whereas qualitative data will be analyzed using structured content analysis. Discussion: This study is expected to provide a comprehensive understanding of the factors that affect ePA adoption and use in Germany. Insights from different perspectives will inform targeted strategies to overcome barriers, strengthen health literacy, and enhance system usability. These insights will contribute to recommendations for optimizing the implementation of the ePA in Germany and promoting the digital transformation of the German healthcare system.

12 September 2025 in Neurological Research and Practice
Verified
Journal Article
Open access
PDF file
DDDuc Chu Dieu
Duc Chu Dieu
HPHelena Franziska Pernice
Helena Franziska Pernice
HMHarisa Muratovic
Harisa Muratovic
PWPaul J. Wetzel
Paul J. Wetzel
GBGina Barzen
Gina Barzen
KHKatrin Hahn
Katrin Hahn
Background: Hereditary transthyretin amyloidosis is a rapidly progressive and lethal disease. Thanks to the increasing number of disease-modifying treatments, prognosis has improved significantly. However, new challenges regarding treatment response and when to change treatment remain unanswered. The objective of this study was to evaluate rationales for treatment switches from the past and to formulate learnings for future management. Methods: In this retrospective single center study, we analyzed real-world data of 13 patients with hereditary transthyretin amyloidosis undergoing single or multiple treatment switches before January 2024. Data involved demographic characteristics as well as reasons for treatment switches in a descriptive and exploratory manner. Available amyloid specific therapies during the study period included tafamidis 20 mg, tafamidis 61 mg, patisiran, inotersen and vutrisiran. Results: Switches from tafamidis 20 mg were most frequently due to disease progression (83.3%). Patisiran transitions predominantly occurred following vutrisiran’s approval, driven by preference for subcutaneous administration and extended dosing intervals (65.0%). Two cases of switches from inotersen were both associated with severe adverse effects. Conclusions: In this study, reasons for treatment switches were manifold, encompassing disease progression, the occurrence of adverse events, patient preferences and/or the availability of newly approved drugs. Hence, multidimensional consideration of these reasons remains pivotal in guiding the subsequent choice of medication in particular and managing hereditary transthyretin amyloidosis in general.

5 November 2022 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
GBGina Barzen
Gina Barzen
KSKarl Stangl
Karl Stangl
JBJens-Uwe Blohmer
Jens-Uwe Blohmer
WHWolfgang Henrich
Wolfgang Henrich
TDThomas Dörner
Thomas Dörner
VSVerena Stangl
Verena Stangl
Background: Due to the increasing prevalence of Kawasaki Disease (KD) in adulthood, the number of women considering pregnancy is growing. There are limited data on the course of pregnancy in KD with coronary artery involvement. Case summary: We report on the pregnancy outcome of a 30-year-old woman with KD who was successfully resuscitated for ventricular tachycardia 3 years before. At that time, bypass surgery and later implantable cardioverter-defibrillator implantation were performed because of thrombotically occluded calcified giant coronary aneurysms. The pregnancy course was initially uncomplicated, however, at 31 weeks of gestation, left-sided breast cancer was diagnosed. Weighing maximum therapeutic efficacy against acceptable foetal and maternal cardiotoxic risk, our multidisciplinary team decided on neoadjuvant chemotherapy. The mother and foetus tolerated the therapy well. However, at 36 weeks of gestation, due to HELLP (haemolysis, elevated liver, low platelets) syndrome, a caesarean section had to be performed. The newborn was healthy with good APGAR (appearance, pulse, grimace, activity, respiration) scores. Three weeks after delivery, chemotherapy was restarted and at Week 4 after the caesarean section, the tumour was no more detectable. Discussion: We discuss data on pregnancy and KD and outline that pregnancy can be considered if the clinical condition is good and left ventricular function is preserved. We also address possible therapeutic approaches and care for breast cancer in pregnancy and coexisting cardiovascular disease. The extraordinary importance of interdisciplinary cooperation between different disciplines in such complex clinical disease conditions is emphasized.

28 December 2023 in Vaccine
Verified
Journal Article
Closed access
GBGina Barzen
Gina Barzen
FRFinn Rieber
Finn Rieber
KSKarl Stangl
Karl Stangl
KHKatrin Hahn
Katrin Hahn
SSSebastian Spethmann
Sebastian Spethmann

13 March 2026 in JMIR Preprints
Verified
Preprint
Open access
SMSusann May
Susann May
MMManuela Marquardt
Manuela Marquardt
GBGina Barzen
Gina Barzen
FSFrances Seifert
Frances Seifert
MNMary Nyarko
Mary Nyarko
FMFelix Muehlensiepen
Felix Muehlensiepen
BACKGROUND Nationwide electronic health records (EHRs) are intended to strengthen patient empowerment and improve information continuity in healthcare. In Germany, the electronic patient record (elektronische Patientenakte, ePA) transitioned from an opt-in to an opt-out model in 2025. Although an ePA is now automatically created for all individuals with statutory health insurance, active use remains voluntary and uptake has been limited. Initial survey data suggest that technical complexity and access requirements may hinder engagement, yet little is known about how insured individuals experience the setup and authentication process. OBJECTIVE This study aimed to explore how insured persons experience the registration and authentication process of the ePA app and to identify barriers that influence successful access. METHODS We conducted a qualitative study based on semi-structured interviews with 23 individuals covered by statutory health insurance in Germany who had experience with or had attempted to initiate the ePA registration process. Data were analyzed using Kuckartz’s structured qualitative content analysis. In addition to phase-specific challenges, cross-phase patterns were inductively condensed into higher-order forms of selectivity shaping access to the ePA. RESULTS Participants described the ePA setup not as a single technical step but as a multi-stage process comprising five sequential phases: orientation, technical entry, verification, interruption, and integration. Barriers accumulated across phases and included fragmented app structures, complex multi-step authentication procedures, technical breakdowns, administrative inconsistencies, and prolonged waiting times. Successful completion of the process depended heavily on individual coping resources such as digital competence, persistence, and self-efficacy. Across the material, five interrelated forms of selectivity were identified: cognitive, capability-based, affective, procedural, and technical-infrastructural selectivity. These mechanisms interacted cumulatively, rendering the authentication pathway selectively passable and prone to dropout, even among digitally competent users. CONCLUSIONS Access to the opt-out ePA is structured by processual and structural selectivity rather than isolated technical problems. Formal universality does not guarantee effective usability. To prevent the reproduction of digital inequalities, implementation strategies must address cumulative burdens across the entire authentication pathway and shift responsibility from individual user capabilities toward coherent system design and supportive infrastructures. CLINICALTRIAL https://www.drks.de/search/de/trial/DRKS00037053 identifier DRKS00037053, Registration Date: 05.06.2025 INTERNATIONAL REGISTERED REPORT RR2-10.1177/20552076251407130